Clinical Trial Update: Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on DLI-X as a prophylactic and therapeutic donor lymphocyte infusion to prevent or treat leukemia relapse after hematopoietic cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma
• Undifferentiated Leukemia

Drugs mentioned

• DLI-X

Snippet

Sponsor: University of Arizona | Conditions: Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Status: NOT_YET_RECRUITING